Shionogi presents New Data on Cefiderocol (S-649266), a Siderophore Cephalosporin, and S-033188 a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza at ECCMID 2017

OSAKA, Japan–(BUSINESS WIRE)–Shionogi & Co., Ltd. today announced it will be presenting new data on cefiderocol (S-649266), an investigational siderophore cephalosporin in late stage development with activity against a broad range of Gram-negative pathogens, including those highly resistant to currently available agents such as colistin and carbapenem-resistant strains of Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae (CRE) and Stenotrophomonas maltophilia, and S-033188, an investigational cap-dependent endonuclease inhibitor targeting influenza at this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held in Vienna, Austria, April 22 – 25, 2017.

Highlights of cefiderocol presentations include first time clinical trial efficacy results, as well as supportive in vitro data, and S-033188 presentations will showcase both clinical and non-clinical data (e.g., non-clinical efficacy against avian influenza virus A/H5N1).

Below is an overview of the oral and poster presentations featuring cefiderocol and S-033188 at ECCMID 2017:

Session Title     Presentation    

Abstract Number &
Presentation Information

Late-breaker: Recent clinical trials     Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS*-cUTI)    

Abstract #7582
Oral Presentation
Saturday, April 22, 2017
17:09-17:20 PM
Presenter: Simon Portsmouth

Advances in Japanese Chemotherapy     Mode of action of cefiderocol, a novel siderophore cephalosporin, active against highly resistant Gram-negative bacteria including carbapenem-resistant strains of Enterobacteriaceae and non-fermenting bacteria    

Abstract #3177
Oral Presentation
Monday, April 24, 2017
14:54-15:04 PM
Presenter: Yoshinori Yamano

Cefiderocol     In vitro activity of cefiderocol against globally collected carbapenem-resistant Gram-negative bacteria including isolates resistant to ceftazidime/avibactam, ceftolozane/tazobactam and colistin: SIDERO-CR-2014/2016 study    

Poster #1316
Poster Presentation
Monday, April 24, 2017
12:30-13:30 PM
Presenter: Yoshinori Yamano

Surveillance of cefiderocol in vitro activity against Gram-negative clinical isolates collected in Europe: SIDERO-WT-2014    

Poster #1314
Poster Presentation
Monday, April 24, 2017
12:30-13:30 PM
Presenter: Masakatsu Tsuji

    The in vitro activity of cefiderocol, a siderophore cephalosporin, against a global collection of Stenotrophomonas maltophilia    

Poster #1313
Poster Presentation
Monday, April 24, 2017
12:30-13:30 PM
Presenter: Masakatsu Tsuji

Session Title     Presentation    

Abstract Number &
Presentation Information

Advances in Japanese chemotherapy     Pharmacokinetic/pharmacodynamic analysis of S-033188, an influenza Cap-dependent endonuclease inhibitor, from a phase 2, randomized, double-blind, placebo-controlled study in otherwise healthy adults with seasonal influenza    

Abstract #1033
Oral Presentation
Monday, April 24, 2017
15:18-15:28 PM
Presenter: Takeki Uehara

Novel and improved therapeutical approaches to viral infections One day oral dosing of S-033188, a novel inhibitor of influenza virus Cap-dependent endonuclease, exhibited significant reduction of viral titer and prolonged survival in mice infected with influenza B virus    

Poster #1971
Poster Presentation
Tuesday, April 25, 2017
12:30-13:30 PM
Presenter: Takao Shishido

Pharmacokinetic and pharmacodynamic analysis of S-033188/S-033447, a novel inhibitor of influenza virus Cap-dependent endonuclease, in mice infected with influenza A virus    

Poster #1973
Poster Presentation
Tuesday, April 25, 2017
12:30-13:30 PM
Presenter: Takeshi Noshi

    Inhibitory effect of S-033188/S-033447, a novel inhibitor of influenza virus Cap-dependent endonuclease, against highly pathogenic avian influenza virus A/H5N1    

Poster #1974
Poster Presentation
Tuesday, April 25, 2017
12:30-13:30 PM
Presenter: Keiichi Taniguchi


Cefiderocol—an investigational antibiotic agent1

Cefiderocol is a siderophore cephalosporin with a novel mechanism for efficiently penetrating the outer cell membrane of Gram-negative pathogens. Cefiderocol binds to ferric iron and is actively transported into bacterial cells through the outer membrane via the bacterial iron transporters which function to incorporate this essential nutrient for bacteria.2 This Trojan Horse strategy allows cefiderocol to achieve higher concentrations in the periplasmic space where it can then bind to receptors and inhibit cell wall synthesis in the bacterial cells.3 In addition, cefiderocol is stable against all known classes of beta-lactamases, including both the metallo- and serine-carbapenemases.4 Data from global surveillance studies for cefiderocol demonstrated potent in vitro activity against a wide spectrum of Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae and Stenotrophomonas maltophilia.5

About the regulatory pathway of cefiderocol

Cefiderocol is currently in clinical development and recently completed a US registrational study in patients with cUTI (APEKS*-cUTI). An additional Phase 3 trial in patients with carbapenem-resistant pathogens at various infection sites (CREDIBLE-CR) is ongoing. In 2017 Shionogi will initiate a Phase 3 HAP/VAP/HCAP† (APEKS*-NP‡) clinical trial. The Company plans to submit a new drug application to the U.S. FDA in 2017 and to the EMA in 2018. Information is available at under the identifiers NCT02321800, NCT02714595 and NCT03032380, respectively.

* Acinetobacter, Pseudomonas, Escherichia, Klebsiella and Stenotrophomonas
Hospital-Acquired Pneumonia/Ventilator-Acquired Pneumonia/Healthcare-Associated Pneumonia
Nosocomial Pneumonia

About Influenza

Epidemic and pandemic influenza remain a major public health concern, and novel influenza drugs that will offer significant improvement over current therapy are urgently needed. Worldwide, annual influenza epidemics are estimated to result in 3 to 5 million cases of severe illness, and about 250,000 to 500,000 deaths.6 In general, those at highest risk of influenza-associated complications include children under 2 years of age, adults over 65 years of age, pregnant women, and people of any age with certain medical conditions, including chronic heart, lung, metabolic diseases (such as diabetes) and weakened immune systems.

About S-033188

S-033188 is a cap-dependent endonuclease inhibitor with a novel mechanism of action being studied for the treatment of influenza. S-033188 is an investigational product being developed for one-time dosing, and has the potential to be more effective than existing marketed anti-influenza products. Development and commercialization are in collaboration with F. Hoffmann-La Roche Ltd.

About Shionogi

Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and well-being of the patients we serve.” Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders. For over 50 years, Shionogi has developed and commercialized innovative oral and parenteral anti-infectives. In addition, Shionogi is engaged in new research areas, such as obesity/geriatric metabolic disease and oncology/immunology. Contributing to the health and quality of life of patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit For more information on Shionogi Inc., the U.S.-based subsidiary of Shionogi & Co., Ltd., headquartered in Florham Park, NJ, USA, please visit For more information on Shionogi Ltd., the UK-based subsidiary of Shionogi & Co. Ltd., headquartered in London, England, please visit

Forward Looking Statement

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.




Kohira N, West J, Ito A, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinicalisolates, including carbapenem-resistant strains. Antimicrob Agents Chemother. 2015;60(2):729-734.



Ito A, Nishikawa T., Masumoto S, et al. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60(12).



Tillotson GS. Trojan Horse Antibiotics—A Novel Way to Circumvent Gram-Negative Bacterial Resistance? Infectious Diseases: Research and Treatment. 2016;9:45-52 doi:10.4137/IDRT.S31567.



Ito-Horiyama T, Ishii Y, Ito A, et al. Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases. Antimicrob Agents Chemother. 2016;60(7):4384-4386.



M Hackel, M Tsuji, Y Yamano, et al. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, Against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem Non-Susceptible Isolates: The SIDERO-WT-2014 Study. Antimicrobial Agents Chemotherapy (In preparation)


6. WHO website, Influenza (Seasonal), Fact sheet N°211, March 2014


Fujifilm Increases Production Capacity and Establishes New Process Development Facilities with JPY14 Billion ($130M USD) Investment to Support Growing Market Demand

TOKYO–(BUSINESS WIRE)–FUJIFILM Corporation (President: Kenji Sukeno) will increase production capacity by investing about JPY14 billion ($130m) in the USA and UK in order to expand the business of its BioCDMO Division.

In the USA, at FUJIFILM Diosynth Biotechnologies Texas, LLC (FDBT), a JPY10 billion ($93m) cGMP production facility has been completed. This facility was built in part with funding from BARDA (Biomedical Advanced Research and Development Authority), an office of the U.S. Department of Health and Human Services, and Fujifilm plans to invest an additional JPY3 billion ($28m) to outfit the facility with mammalian cell culture bioreactors. This facility will start operation at the beginning of 2018. FUJIFILM Diosynth Biotechnologies Texas, LLC (FDBT) was acquired by Fujifilm through FUJIFILM Diosynth Biotechnologies U.S.A., Inc. (FDBU) in 2014. In March of this year, FDBT became a wholly owned subsidiary of FDBU exercising the option early included in the initial deal to take 100% ownership. In addition, a JPY1 billion ($9m) investment will be made to expand the Process Development capabilities at FUJIFILM Diosynth Biotechnologies UK Limited near to its Billingham, UK site. This facility is scheduled to be operational in summer of 2017.

The FDBT facility will be the manufacturing center of excellence for the company’s Saturn Monoclonal Antibody Platform with an initial cell culture capacity of 6,000L (3X 2000L bioreactors). The design of the facility allows for future expansion that can accommodate up to 24,000L of upstream capacity to meet much needed customers’ clinical and commercial demands. In the United Kingdom, the investments include the establishment of a dedicated Mammalian Cell Culture Center of Excellence. These laboratories span over 10,000 sq. ft. and are designed to incorporate the latest high-throughput technologies, including fully automated bioreactors and chromatography systems, to enable for rapid and efficient monoclonal antibody manufacturing process readiness. These assets will enable Fujifilm to provide ‘best in class’ facilities, technology and operational know how to the industry. They are also a key in our continuing commitment to develop future Medical Counter Measures and Pandemic Flu response candidates for our long term Partners the CIADM (Center for Innovation in Advanced Development and Manufacturing), BARDA and other third party customers.

“FUJIFILM Diosynth Biotechnologies is committed to its vision of being Leaders in the Bio CDMO space,” said Steve Bagshaw, Chief Executive Officer, FUJIFILM Diosynth Biotechnologies, “Our commitment is to transform the CDMO business through innovation and with our great people – providing long term support to our partners fulfilling our core purpose as ‘Partners for Life – Advancing tomorrow’s medicines’.”

Biopharmaceutical production requires the use of advanced manufacturing technologies and facilities for culturing, separation and purification. The number of companies outsourcing process development and manufacturing activities of biopharmaceuticals to CDMOs is increasing. The contract development and manufacturing market is projected to achieve growth of 8% per annum* accordingly.

Fujifilm will continue to grow and expand its existing capabilities in addition to engaging in external collaborations to increase capacity, and it will further develop high efficiency and high productivity technology by combining group technologies, to continue to grow further the business. It is targeting sales of JPY100 billion in its BioCDMO business by 2023.

* According to Fujifilm data

About Fujifilm

FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Billingham, UK, RTP, North Carolina and College Station, Texas. FUJIFILM Diosynth has over twenty five years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to:

FUJIFILM Holdings Corporation, Tokyo, Japan (TOKYO: 4901) brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit:

Fitbit Schedules Q117 Financial Results for May 3, 2017

SAN FRANCISCO–(BUSINESS WIRE)–Fitbit (NYSE: FIT), the leader in the connected health and fitness market, today announced that it expects to release results for its first quarter of 2017 on Wednesday, May 3, after market close. In conjunction with a press release, management will host a conference call at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time that afternoon.

A free, live webcast of the conference call will be available on the Investor section of the company’s website at

The call can also be accessed by dialing (888) 337-8165 or (719) 325-2111, access code 9381139. A replay of the call will be archived on the Company’s website for the following six months.

About Fitbit, Inc. (NYSE:FIT)

Fitbit helps people lead healthier, more active lives by empowering them with data, inspiration and guidance to reach their goals. As the leader in the connected health and fitness category, Fitbit designs products and experiences that track everyday health and fitness. Fitbit’s diverse line of award-winning products includes Fitbit Surge®, Fitbit Blaze™, Fitbit Charge 2™, Alta HR™, Alta™, FitbitFlex 2™, Fitbit One® and Fitbit Zip® activity trackers, as well as the Aria® Wi-Fi Smart Scale. Fitbit products are carried in 54,000 retail stores and in 65 countries around the globe. Fitbit Group Health uses the power of the Fitbit activity trackers, software and services to deliver innovative solutions for corporate wellness, weight management, insurance and clinical research. Fitstar by Fitbit offers a digital health and fitness platform that helps and inspires users to get fit anytime, anywhere, and has a footprint of over 8.3 million downloads across the Fitstar Personal Trainer and Fitstar Yoga apps, with availability in 155 countries.

Fitbit and the Fitbit logo are trademarks or registered trademarks of Fitbit, Inc. in the U.S. and other countries. Additional Fitbittrademarks can be found at Third-party trademarks are the property of their respective owners.

Connect with us on FacebookInstagram or Twitter and share your Fitbit experience.

CORRECTING and REPLACING Theranos Reaches Resolution with Centers for Medicare & Medicaid Services

PALO ALTO, Calif.–(BUSINESS WIRE)–The phone number for company contact Tali Mackay should read 650-546-2321 (instead of 512-736-1343).

The corrected release reads:


CMS withdraws revocation of CLIA certificates and reduces civil monetary penalty; Theranos withdraws appeal, completing exit from the clinical lab business

Theranos, Inc. announced today that it had reached a global settlement agreement with the Centers for Medicare & Medicaid Services (CMS) that resolves all outstanding legal and regulatory proceedings between CMS and Theranos. Pursuant to the terms of the settlement, CMS has withdrawn the revocation of the company’s CLIA operating certificates and reduced its civil monetary penalty against the company to $30,000.

As part of the agreement, Theranos affirmed that, consistent with the business plans it outlined last fall, the company will not own or operate a clinical laboratory within the next two years. Theranos exited the clinical lab and retail business last year, and is focusing on its miniaturized, automated testing platforms and related chemistries. The Company looks forward to working with regulatory authorities to secure approval for these innovative technologies.

The company is also withdrawing its September 2015 appeal of the sanctions imposed by CMS on its Newark clinical laboratory.

About Theranos

Founded in 2003 by Elizabeth Holmes, Theranos, Inc. is a health technology company headquartered in Palo Alto, Calif. Its proprietary miniLab platform is designed to enable earlier disease detection and intervention by facilitating low-cost, small-sample collection, testing, and rapid communication of diagnostic information in distributed settings. To learn more about Theranos, visit

Exscudo, Cryptocurrency Financial Services Provider Releases Its First Video Message

The leaders of Exscudo – a cryptocurrency financial service provider, tell the audience more about the project in their new video.

​​The cryptocurrency linked financial services platform, Exscudo announces the release of the latest interview video featuring the top managers. In the video, Alex Sitnikov (CTO), Julian Kossinov (CFO), and Andrew Zimine (CEO) shed more light on the project to help the cryptocurrency community and general public understand the platform and its products. Exscudo’s products have a lot of aspects to them, including innovative IT solutions and functions in a new legal field. The new financial ecosystem is being turned into a reality by relentless efforts of specialists from various fields.

Alex Sitnikov, a highly-qualified developer who has vast experience working in IT-development for major traditional stock exchanges and companies, gives some information on how the whole system works. The core of Exscudo is its Stock Exchange, on which EON color coins are traded instead of fiat and cryptocurrencies themselves. The secure feature makes it impossible for hackers or cybercriminals to steal from the exchange as the exchange doesn’t store any money and all funds belonging to the users involved in transactions either remain in wallets or bank accounts until the last moment of closing the order.

Exscudo bridges the gap between traditional institutions and cryptocurrencies in the financial sector. In order to facilitate efficient cooperation between these financial institutions, the company is registered in the EU legislation zone, ensuring full compliance with all applicable financial regulations, anti-money laundering in particular. In the interview, Kossinov states that the top priority of the company is to introduce a seamless exchange procedure not only for cryptocurrencies but also for cryptocurrency-fiat pairs.

The company’s CEO Andrew Zimine believes that cryptocurrencies are meant to change the world. That’s why Exscudo has developed a number of products to solve the problems of accessibility, transparency, and sustainability of the financial market. Zimine, describing Exscudo’s underlying idea says,

“This is your personal access to the financial world, right from any device and for any man on Earth, without intermediaries.”

Exscudo uses an in-house designed distributed network called EON which empowers the whole system. The technology also enables the emission of EON coins that function as the fuel of blockchain and ICO assets. The company will release a total of 240 million EON coins, of which 150.72 million will be available for sale during the ICO scheduled to start on April 25, 2017. The price for 1 EON will be 0.0002 BTC.

Exscudo offers products and services for different groups of users. Institutional investors get an opportunity to invest in the cryptocurrency market with Exscudo Exchange legally. E-commerce businesses and brick-and-mortar stores will be able to accept cryptocurrencies for payment easily and legally with the company’s Merchant platform. Traders from traditional markets will be pleased with professional desktop and mobile terminals that deliver the ultimate trading experience while offering a bird’s eye view of all market data. Individual investors, cryptocurrency miners and even people who are not working on the crypto market can soon make use of Exscudo Channels, the mobile wallet, and secure messenger. The app offers a broad range of functions for storage and exchange of currencies, payments, secure communications and even monetization of public channels.

About Exscudo

Exscudo is the gateway between the traditional economy and the cryptocurrency market. The platform’s main aim is to create an easy-to-use, fast, legal and secure access to the cryptocurrency market for every person with access to the internet and credit card. The platform is in the process of building an entire ecosystem with a range of tools to meet the requirements of people irrespective of whether they are familiar with cryptocurrencies or not.

Learn more about the platform here
Join Exscudo ICO here
Watch the Exscudo Video at –

Media Contact

Contact Name: Ekaterina Kozyreva
Contact Email:
Location: Tallinn, Estonia

Exscudo is the source of this content. Virtual currency is not legal tender, is not backed by the government, and accounts and value balances are not subject to consumer protections. This press release is for informational purposes only. The information does not constitute investment advice or an offer to invest.

Source: Exscudo

Pulse Center for Patient Safety Announces June 2017 Family-Centered Patient Advocacy Training

Who will be YOUR advocate when you need one? Join with a friend or family member and see how to work together.

​Pulse Center for Patient Safety Advocacy & Education (formerly PULSE of NY) today announced its next round of Family-Centered Patient Advocacy Training. It will be held over three weeks in June 2017 at Hofstra University in Hempstead, NY.

Pulse President Ilene Corina, who will teach the course, asks, “Have you ever wondered how you, as a patient, might communicate better with members of the medical profession? Have you been an advocate for a friend or family member and had to support them as they navigated the health care system? Or maybe you have thought about becoming a professional patient advocate.”

“Have you ever wondered how you, as a patient, might communicate better with members of the medical profession?

Ilene Corina, President, PULSE Center for Patient Safety Education & Advocacy

The Family-Centered Patient Advocacy training program was developed by Pulse CPSEA ( with input from national experts in patient safety. This course teaches the history of patient safety, medication safety, health literacy, communication skills, and much more, and helps participants learn to be active partners with the medical team and provide a voice for themselves or others.

This course is open to all individuals regardless of prior knowledge and skills, including those working in the medical and related health fields. Course participants will receive a Certificate of Completion. Enrollment is limited. Course includes monthly follow-up communication with the instructor via phone or email.

The course will be held at Hofstra over three consecutive Saturday’s, June 3, 10 and 17 from 9:00 am until 12:00 noon. Attendance at all three classes is required to earn the Certificate. Total cost of the course is $175.

To register, or for more information, please click here or call 516-463-7200.

Source: Pulse Center for Patient Safety Education & Advocacy

European Commission Publishes Scientific Advices Related to Breast Implants and Health

On 7 April 2017, the European Commission and its Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) published two Scientific Advices related to breast implants and health, requested by the European Commission. These are on 1) new scientific information on the safety of PIP breast implants and 2) the possible association between breast implants and anaplastic large cell lymphoma (ALCL).

The first piece of advice concerns whether there is sufficient new scientific information on the safety of PIP breast implants to warrant an update of the 2014 Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) Opinion. Based on the scientific information it has gathered and evaluated, the SCHEER concludes that this is not the case at present. See full advice.

The second piece of advice is on the state of scientific knowledge on a possible association between breast implants and ALCL. The SCHEER was asked to determine whether sufficient scientific information is available for conducting a full risk assessment. The SCHEER concluded that, at present, there is insufficient scientific information available to establish a methodologically robust risk assessment on the potential association of breast implants with the development of ALCL. See full advice.

A Public Hearing on these two Scientific Advices will be organised on 29 May in Luxembourg, which aims to present and discuss the scientific basis of these two. Candidates must have appropriate expertise in the field, be able to present and understand the scientific arguments and meet other criteria. Interested parties are invited to register by 7 May 2017.

ESMO 2017: Travel Grants for Patient Advocates

Travel grant recipients will be selected by the ESMO Patient Advocacy Working Group who will evaluate the individual applications and allocate the grants accordingly.

How to apply

To apply for a grant, please send your CV and a letter of motivation, proving that part of your time is dedicated to cancer advocacy. All applicants should be proficient in English.

Please send your application by e-mail to: with the subject line: ESMO Advocacy 2017 – travel grant – your name

Application deadline

The deadline for receipt of applications is 31 May 2017. Successful applicants will be notified in the first half of June 2017.

Additional requests received after the deadline, will be kept in a waiting list and processed at a later stage, based on the amount of financial support still available.

Each grant will reimburse travel and accomodation costs up to a maximum of 800 EUR. Reimbursements will be made after the congress, and upon receipt of original travel and accommodation bills/invoices.

Thanks to the generosity of our sponsors, we look forward to welcoming a large number of patient advocates from across Europe!